Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

53.46 +0.15 (+0.28%)
Official Closing Price Updated: 7:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
1 Top ETF I Plan to Load Up on in 2026 ↗
This ETF could produce robust total returns in 2026 and beyond. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical... 
Via MarketMinute
Topics Intellectual Property
News headline image
2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the... 
Via StockStory
Topics Stocks
News headline image
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
2 Dividend Stocks to Scoop Up Without Hesitation Right Now ↗
These stocks can be great sources of portfolio growth in the years ahead. 
Via The Motley Fool
Topics Bankruptcy Initial Public Offering
News headline image
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026? ↗
The stock has been on the rebound for several months, but can it keep the momentum going? 
Via The Motley Fool
Topics Intellectual Property
News headline image
The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year
As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever ↗
Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
3 Drug Stocks to Buy at a Discount ↗
The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever ↗
If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Co (NYSE:BMY) Presents a Classic Value Investing Case Amid Transition ↗
Bristol Myers Squibb (BMY) presents a classic value investing case, trading at a significant discount with strong profitability and a high dividend yield, despite near-term patent challenges. 
Via Chartmill
Topics Intellectual Property
News headline image
Dividend Stocks Are the Gift that Will Keep On Giving You More Income in 2026 ↗
These dividend investments can provide you with a growing income stream in 2026. 
Via The Motley Fool
Topics Economy
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave
As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The... 
Via MarketMinute
Topics Economy
News headline image
Should Retirees Pull Their Money Out of the Stock Market in 2026? ↗
Even if you think the market will slump, selling your holdings isn't an ideal strategy. 
Via The Motley Fool
Topics ETFs Economy Retirement
News headline image
Bristol-Myers Squibb Co (NYSE:BMY) Offers a High-Quality Dividend Profile for Income Investors ↗
Bristol-Myers Squibb (BMY) offers a high 4.92% dividend yield with a strong growth history, backed by solid earnings and a satisfactory financial condition for income investors. 
Via Chartmill
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief. 
Via Stocktwits
Topics Government World Trade
News headline image
This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗
This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
These 2 Healthcare Stocks Just Declared Dividend Raises ↗
The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
News headline image
Why Bristol-Myers Squibb (BMY) Stock Is Up Today
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 3.7% in the afternoon session after BofA Securities upgraded the company's stock from "Neutral" to "Buy" and increased its... 
Via StockStory
News headline image
Stay informed with the top movers within the S&P500 index on Monday. ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Bristol Myers Squibb (BMS): Navigating the Patent Cliff with a Renewed Pipeline and Strategic Acquisitions
Date: December 15, 2025 1. Introduction Bristol Myers Squibb (BMS) (NYSE: BMY) is a global biopharmaceutical powerhouse focused on discovering, developing, manufacturing, and distributing innovative... 
Via PredictStreet
Topics Intellectual Property Lawsuit Supply Chain
News headline image
Top S&P500 movers in Monday's pre-market session ↗
The US market session of Monday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
2 Dividend Stocks to Double Up on Right Now ↗
These dividend growth machines could have considerable upside for long-term investors. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
The Smartest Dividend Stocks to Buy With $1,000 Right Now ↗
Here are three stocks offering attractive yields of up to 4.9%, each backed by strong businesses. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Which S&P500 stocks are moving on Friday? ↗
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.